Zomedica has partnered with Seraph Biosciences, Inc. to develop their in-clinic diagnostic analyzer for use in the detection of pathogens in companion animals. The ZM-020 diagnostic platform has the potential to screen for a wide range of pathogens in companion animal feces, urine, respiratory, and dermatological samples in minutes without the need for extensive sample prep or the use of reagents. The first tests Zomedica expects for release with the ZM-020 diagnostic platform will focus on the rapid detection of fecal parasites, potential UTI-associated urine bacteria and crystals, and leptospirosis using urine samples.

1. Advances in Infecti on Detecti on Technology at the Point of Care

Zomedica has partnered with Qorvo Biotechnologies, LLC to collaborate on the development of a collection of rapid veterinary diagnostic assays with the goal to deliver reference-lab performance at the point of care. TRUFORMA™, formerly ZM-024, is expected to be comprised of a table-top instrument that uses disposable assay cartridges to test a range of samples including whole blood, serum, and plasma. Joint development work initially targets five assay candidates to detect certain thyroid and adrenal disorders in dogs and cats, which currently require reference lab immunoassay testing for reliable diagnostic results. TRUFORMA™  is an investigational device, not currently available for sale and limited to investigational use only. Assays in Development: Feline Total T4, Feline TSH, Canine TSH, Canine Free T4, Canine Cortisol, Canine eACTH

1. Thyroid-Stimulating Hormone (TSH) Assay
2. Total Thyroxine (TT4)
3. Product Brief

Zomedica has partnered with Celsee, Inc. to develop their circulating tumor cell (CTC) “liquid biopsy” platform for use by veterinarians as a canine cancer diagnostic. ZM-017 aims to enable veterinarians to detect canine cancers in a manner that is faster, more affordable and less invasive compared to existing methods, which can be expensive and cost prohibitive for pet owners. The first assay Zomedica expects for release with ZM-017 targets hard-to-diagnose canine cancers, such as hemangiosarcoma and osteosarcoma.

1. Liquid Biopsy in Veterinary Medicine